Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response
暂无分享,去创建一个
[1] E. Sokol,et al. Genomic landscape of pleural and peritoneal mesothelioma tumours , 2022, British Journal of Cancer.
[2] J. Kirkwood,et al. Molecular Pathways and Mechanisms of LAG-3 in Cancer Therapy. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] A. Mansfield,et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Aerts,et al. Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition. , 2022, Lung cancer.
[5] M. de Perrot,et al. IRF3 Knockout Results in Partial or Complete Rejection of Murine Mesothelioma , 2021, Journal of clinical medicine.
[6] Jiang Liu,et al. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma , 2021, Clinical Cancer Research.
[7] M. Ladanyi,et al. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study , 2021, The Lancet. Digital health.
[8] C. Swanton,et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment , 2021, Nature Communications.
[9] H. Rehrauer,et al. Endogenous retrovirus expression activates type-I interferon signaling in an experimental mouse model of mesothelioma development. , 2021, Cancer letters.
[10] Ju-Seog Lee,et al. Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma , 2021, bioRxiv.
[11] A. Giordano,et al. Assessment of the Carcinogenicity of Carbon Nanotubes in the Respiratory System , 2021, Cancers.
[12] A. Mansfield,et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.
[13] R. Asciak,et al. Update on biology and management of mesothelioma , 2021, European Respiratory Review.
[14] J. V. van Meerbeeck,et al. The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3 , 2021, Cancers.
[15] Harinder Singh,et al. SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators , 2020, bioRxiv.
[16] R. Schmid,et al. Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] M. Ladanyi,et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma , 2019, Modern Pathology.
[18] M. V. van Vugt,et al. Inflammatory signaling in genomically instable cancers , 2019, Cell cycle.
[19] Ash A. Alizadeh,et al. Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.
[20] Faraz Hach,et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma , 2018, Genome Medicine.
[21] David L. Gibbs,et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. , 2018, Cancer discovery.
[22] R. Dolcetti,et al. Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance , 2018, Front. Oncol..
[23] Z. Zeng,et al. BCL6B suppresses proliferation and migration of colorectal carcinoma cells through inhibition of the PI3K/AKT signaling pathway , 2018, International journal of molecular medicine.
[24] Craig A. Poland,et al. Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf) , 2017, Current Biology.
[25] K. Leffondré,et al. Dose-time-response association between occupational asbestos exposure and pleural mesothelioma , 2017, Occupational and Environmental Medicine.
[26] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[27] Chao Cheng,et al. Immunoregulatory functions of VISTA , 2017, Immunological reviews.
[28] R. Verardo,et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer , 2016, Oncotarget.
[29] Thomas D. Wu,et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.
[30] X. M. Sun,et al. Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease , 2016, Cell Death and Differentiation.
[31] F. Galateau-Sallé,et al. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] M. Becich,et al. High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] J. Herman,et al. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU , 2015, Oncotarget.
[34] Piotr J. Balwierz,et al. ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs , 2014, Genome research.
[35] M. Carbone,et al. Asbestos is not just asbestos: an unrecognised health hazard. , 2013, The Lancet. Oncology.
[36] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[37] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[38] M. Emi,et al. Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma , 2012, Cancer science.
[39] F. Galateau-Sallé,et al. Molecular changes in mesothelioma with an impact on prognosis and treatment. , 2012, Archives of pathology & laboratory medicine.
[40] H. Hoogsteden,et al. Expression Profiling-Based Subtyping Identifies Novel Non-small Cell Lung Cancer Subgroups and Implicates Putative Resistance to Pemetrexed Therapy , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[41] N. Cox,et al. Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.
[42] C. Sander,et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.
[43] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[44] David C. Gondek,et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses , 2011, The Journal of experimental medicine.
[45] T. Burki. Health experts concerned over India's asbestos industry , 2010, The Lancet.
[46] B. Robinson,et al. Advances in malignant mesothelioma. , 2005, The New England journal of medicine.
[47] M. Hatano,et al. Binding of BAZF and Bc16 to STAT6-binding DNA sequences. , 2001, Biochemical and biophysical research communications.
[48] P. Grambsch,et al. Modeling Survival Data: Extending the Cox Model , 2000 .
[49] Yuzhuo,et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma , 2019, Genome Medicine.